Amgen's new research and development facility in San Francisco. (courtesy photo) Shares of Thousand Oaks-based Amgen gained 12% on May 3, one day after the company disclosed its earnings for the first quarter of 2024 and highlighted the excitement around its weight-loss drug. During the company’s earnings call, Amgen CEO Bob Bradway commented on their